STRYKER CORP SYK
Last close
303.13
2026-09-04
Market cap
$116.27B
2026-06-30 share count
52-week range
281.00 - 395.90
Valuation FY2025 figures against the last close
P/S4.6x
P/E36.1x
P/FCF27.1x
EV/EBITDA19.8x
Dividend yield1.1%
Diluted EPS8.40
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.12B | $22.59B | $20.50B | $18.45B | $17.11B | $14.35B | $14.88B | $13.60B | $12.44B | $11.32B |
| Cost of revenue | $9.05B | $8.15B | $7.44B | $6.87B | $6.14B | $5.29B | $5.19B | $4.66B | $4.26B | $3.82B |
| Gross profit | $16.07B | $14.44B | $13.06B | $11.58B | $10.97B | $9.06B | $9.70B | $8.94B | $8.18B | $7.50B |
| R&D | $1.62B | $1.47B | $1.39B | $1.45B | $1.24B | $984.0M | $971.0M | $862.0M | $787.0M | $715.0M |
| SG&A | $8.65B | $7.68B | $7.11B | $6.39B | $6.43B | $5.36B | $5.36B | $5.10B | $4.55B | $4.14B |
| Total operating expenses | $11.18B | $10.75B | $9.17B | $8.74B | $8.38B | $6.83B | $6.98B | $6.40B | $5.88B | $5.33B |
| Operating income | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B | $2.22B | $2.71B | $2.54B | $2.30B | $2.17B |
| Interest expense | $607.0M | $409.0M | $363.0M | — | — | — | — | — | — | — |
| Pre-tax income | $4.51B | $3.49B | $3.67B | $2.68B | $2.28B | $1.95B | $2.56B | $2.36B | $2.06B | $1.92B |
| Income tax | $1.27B | $499.0M | $508.0M | $325.0M | $287.0M | $355.0M | $479.0M | $1.20B | $1.04B | $274.0M |
| Net income | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B | $1.60B | $2.08B | $3.55B | $1.02B | $1.65B |
| EPS, basic | 8.49 | 7.86 | 8.34 | 6.23 | 5.29 | 4.26 | 5.57 | 9.50 | 2.73 | 4.40 |
| EPS, diluted | 8.40 | 7.76 | 8.25 | 6.17 | 5.21 | 4.20 | 5.48 | 9.34 | 2.68 | 4.35 |
| Shares, diluted (wtd. avg.) | $386.5M | $385.6M | $383.7M | $382.2M | $382.3M | $380.3M | $379.9M | $380.3M | $380.1M | $378.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.01B | $3.65B | $2.97B | $1.84B | $2.94B | $2.94B | $4.34B | $3.62B | $2.54B | $3.32B |
| Short-term investments | $89.0M | $91.0M | $82.0M | $84.0M | $75.0M | $81.0M | $88.0M | — | — | — |
| Receivables | $4.04B | $3.99B | $3.77B | $3.56B | $3.02B | $2.70B | $2.89B | $2.33B | $2.20B | $1.97B |
| Inventory | $5.31B | $4.77B | $4.84B | $4.00B | $3.31B | $3.49B | $2.98B | $2.96B | $2.46B | $2.03B |
| Total current assets | $14.76B | $14.85B | $12.52B | $10.28B | $10.02B | $9.71B | $11.06B | $9.73B | $7.99B | $7.86B |
| Property, plant and equipment | $3.88B | $3.45B | $3.21B | $2.97B | $2.83B | $2.75B | $2.57B | $2.29B | $1.98B | $1.57B |
| Goodwill | $19.29B | $15.86B | $15.24B | $14.88B | $12.92B | $12.78B | $9.07B | $8.56B | $7.17B | $6.36B |
| Other intangibles | $5.68B | $4.39B | $4.59B | $4.88B | $4.84B | $5.55B | $4.23B | $4.16B | $3.48B | $3.51B |
| Total assets | $47.84B | $42.97B | $39.91B | $36.88B | $34.63B | $34.33B | $30.17B | $27.23B | $22.20B | $20.43B |
| Short-term debt | $1.00B | $1.41B | $2.09B | $1.19B | $7.0M | $761.0M | $859.0M | $1.37B | $632.0M | $228.0M |
| Total current liabilities | $7.79B | $7.62B | $7.92B | $6.30B | $4.55B | $5.04B | $4.40B | $4.81B | $3.48B | $3.15B |
| Long-term debt | $14.86B | $12.19B | $10.90B | $11.86B | $12.47B | $13.23B | $10.23B | $8.49B | $6.59B | $6.69B |
| Total liabilities | $25.42B | $22.34B | $21.32B | $20.27B | $19.75B | $21.25B | $17.36B | $15.50B | $12.22B | $10.88B |
| Retained earnings | $20.47B | $18.53B | $16.77B | $14.77B | $13.48B | $12.46B | $11.75B | $10.77B | $8.99B | $8.84B |
| Total equity | $22.42B | $20.63B | $18.59B | $16.62B | $14.88B | $13.08B | $12.81B | $11.73B | $9.98B | $9.55B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.04B | $4.24B | $3.71B | $2.62B | $3.26B | $3.28B | $2.19B | $2.61B | $1.56B | $1.92B |
| Depreciation and amortisation | $1.57B | $1.43B | $1.34B | $1.28B | $1.27B | $1.08B | $1.04B | $966.0M | $859.0M | $752.0M |
| Stock-based compensation | $243.0M | $229.0M | $205.0M | $168.0M | $171.0M | $142.0M | $127.0M | $119.0M | $113.0M | $97.0M |
| Capital expenditure | $761.0M | $755.0M | $575.0M | $588.0M | $525.0M | $487.0M | $649.0M | $572.0M | $598.0M | $490.0M |
| Investing cash flow | -$4.87B | -$3.00B | -$962.0M | -$2.92B | -$859.0M | -$4.70B | -$1.46B | -$2.86B | -$1.61B | -$4.19B |
| Financing cash flow | $113.0M | -$525.0M | -$1.59B | -$749.0M | -$2.37B | -$11.0M | $3.0M | $1.33B | -$794.0M | $2.26B |
| Dividends paid | $1.28B | $1.22B | $1.14B | $1.05B | $950.0M | $863.0M | $778.0M | $703.0M | $636.0M | $568.0M |
| Buybacks | — | — | — | — | $0 | $0 | $307.0M | $300.0M | $230.0M | $13.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000310764-26-000010.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |
| SOLV | Solventum Corp | $15.61B | 10.3x | 0.9% |